The study aims to uncover the immunological basis of Tanshi (phlegm-dampness) constitution—a subhealth type in traditional ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma. Clinical Cancer Research , 2023 ...

The study aims to uncover the immunological basis of Tanshi (phlegm-dampness) constitution—a subhealth type in traditional Chinese medicine ...

Autoimmune diseases: Abnormal dendritic cell activation and presentation of self-antigens may contribute to autoimmune diseases like rheumatoid arthritis, lupus erythematosus, autoimmune myocarditis, ...

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a type of blood cancer that affects immune system cells. It most often affects the skin but can also involve bone marrow and other cell types.

Diakonos Oncology reports that an interim analysis of a Phase I open label trial of its dendritic cell vaccine (DOC1021) showed substantially increased survival of glioblastoma multiforme (GBM ...

Scientists have pinpointed a crucial network of immune cells that allows humans to digest food safely without triggering ...

A dendritic cell vaccine administered before and after autologous stem cell transplant (ASCT) was safe and immunogenic and was associated with durable clinical responses in patients with high-risk ...

Follicular dendritic cell sarcoma in the right chest wall Hongli X and others Medicine (Baltimore), 2020. Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic ...

In a subgroup analysis of the 176-patient trial, however, progression-free survival was significantly better with the dendritic cell therapy in patients with non-epithelioid histology (5.7 vs 2.9 ...

Dendritic Cell Vaccine Before Surgery Promising in HER2+ Breast Cancer — Vaccine led to significant drop in peripherally circulating anti-HER2 T-cell response at week 6.